# Sources

Read October 2026 (full text, Europe PMC fullTextXML).

- Elranatamab PopPK/E-R, Clin Pharmacokinet 2026, doi:10.1007/s40262-026-01663-z, PMC13461831: CRS by dose event (79/183 after first step-up; OR 3.86 exposure, 3.11 tumour burden; no ER at second step-up; >90% no CRS after first full dose).
- Epcoritamab E-R in R/R FL, Clin Pharmacokinet 2026, doi:10.1007/s40262-026-01661-1, PMC13545055: 2-step (127-128 evaluable) vs 3-step (OPT, 81) with hydration and dexamethasone prophylaxis; CRS 49.4% vs 70.0%, grade>=2 9.9% vs 26.9%, tocilizumab 11.1% vs 24.4%; no consistent CRS-exposure association within 3-step; IL-6 profiles.
